XACDURO
Total Payments
$410,264
Transactions
820
Doctors
549
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $261,934 | 709 | 488 |
| 2023 | $148,330 | 111 | 85 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $274,259 | 11 | 66.8% |
| Honoraria | $77,650 | 26 | 18.9% |
| Food and Beverage | $36,310 | 755 | 8.9% |
| Consulting Fee | $19,294 | 16 | 4.7% |
| Travel and Lodging | $2,655 | 10 | 0.6% |
| Education | $96.19 | 2 | 0.0% |
Payments by Type
Research
$274,259
11 transactions
General
$136,005
809 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A National Surveillance Program to Evaluate the In Vitro Potency of Standard-of-Care Antibiotics against Contemporary Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients | La Jolla Pharmaceutical Company | $129,100 | 0 |
| Ex vivo modeling and simulation to guide Sulbactum Durlobactam dosing | La Jolla Pharmaceutical Company | $39,875 | 0 |
| Development and validation for the measurement of sulbactam and durlobactam in plasma free filtrate (PFF), effluent, and plasma via LC-MS/MS | La Jolla Pharmaceutical Company | $30,000 | 0 |
| Y site compatibility with sulbactam-durlobactam | La Jolla Pharmaceutical Company | $25,884 | 0 |
| Physical Compatibility with Sulbactam Durlobactam | La Jolla Pharmaceutical Company | $25,883 | 0 |
| In vitro static time kills with cefepime | La Jolla Pharmaceutical Company | $23,518 | 0 |
Top Doctors Receiving Payments for XACDURO — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , NP | Family | Houston, TX | $115.03 | 1 |
| , M.D | Infectious Disease | Victoria, TX | $115.03 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Largo, FL | $114.75 | 1 |
| , MD | Internal Medicine | Tampa, FL | $114.75 | 1 |
| , DO | Internal Medicine | Tampa, FL | $114.75 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Tampa, FL | $114.75 | 1 |
| , MD | Clinical Cardiac Electrophysiology | Chicago, IL | $113.31 | 1 |
| , M.D | Hospitalist | San Diego, CA | $112.43 | 2 |
| , M.D | Infectious Disease | Huntsville, AL | $110.00 | 1 |
| , M.D | Infectious Disease | Huntsville, AL | $110.00 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Huntsville, AL | $110.00 | 1 |
| , M.D | Infectious Disease | Huntsville, AL | $110.00 | 1 |
| , M.D | Infectious Disease | Huntsville, AL | $110.00 | 1 |
| , CRNP; ACNP-BC | Acute Care | Huntsville, AL | $110.00 | 1 |
| , M.D | Critical Care Medicine | Las Vegas, NV | $109.60 | 1 |
| , M.D | Internal Medicine | Bessemer, AL | $108.31 | 6 |
| , MD | Pediatrics | Orlando, FL | $107.25 | 1 |
| , MD | Infectious Disease | Lexington, KY | $107.10 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $104.91 | 1 |
| , MD | Internal Medicine | Houston, TX | $104.91 | 1 |
| , M.D | Internal Medicine | San Antonio, TX | $104.91 | 1 |
| , M.D | Specialist | Bronx, NY | $104.91 | 1 |
| , DO | Infectious Disease | Round Rock, TX | $104.91 | 1 |
| , MD | Infectious Disease | Memphis, TN | $104.72 | 5 |
| , MD | Infectious Disease | Sugar Land, TX | $103.68 | 4 |
Ad
Manufacturing Companies
- La Jolla Pharmaceutical Company $410,264
Product Information
- Type Drug
- Total Payments $410,264
- Total Doctors 549
- Transactions 820
About XACDURO
XACDURO is a drug associated with $410,264 in payments to 549 healthcare providers, recorded across 820 transactions in the CMS Open Payments database. The primary manufacturer is La Jolla Pharmaceutical Company.
Payment data is available from 2023 to 2024. In 2024, $261,934 was paid across 709 transactions to 488 doctors.
The most common payment nature for XACDURO is "Unspecified" ($274,259, 66.8% of total).
XACDURO is associated with 6 research studies, including "A National Surveillance Program to Evaluate the In Vitro Potency of Standard-of-Care Antibiotics against Contemporary Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients" ($129,100).